S.F. Siegel M.D. , P.A. Lee M.D., Ph.D. , W.A. Rudert M.D., Ph.D. , M. Swinyard M.D. , M. Trucco M.D.
{"title":"Phenotype/Genotype correlations in 21-hydroxylase deficiency","authors":"S.F. Siegel M.D. , P.A. Lee M.D., Ph.D. , W.A. Rudert M.D., Ph.D. , M. Swinyard M.D. , M. Trucco M.D.","doi":"10.1016/S0932-8610(12)80154-X","DOIUrl":null,"url":null,"abstract":"<div><p><em>Study Objective:</em> To correlate phenotype with genotype based on molecular diagnosis in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p><p><em>Design:</em> Polymerase chain reaction amplification, restriction fragment length polymorphism, and allele specific oligonucleotide hybridization were utilized to ascertain eight previously recognized deleterious mutations in affected individuals and their family members.</p><p><em>Participants/Setting:</em> DNA samples were obtained from 20 individuals with 21-hydroxylase deficiency followed through the Endocrine Clinic of the Children's Hospital of Pittsburgh. Fifteen individuals had salt-losing 21-hydroxylase deficiency and two families had two affected individuals. Four individuals presented prior to 5 years of age without salt loss. One individual presented in adolescence with hirsutism and oligomenorrhea.</p><p><em>Main Outcome Measure:</em> Molecular diagnosis of 21-hydroxylase deficiency.</p><p><em>Results:</em> Five patients have homozygous deletions of the promoter region. Two patients are homozygous for the splicing mutation in the second intron. Individual patients were homozygous for the following three mutations: Arg<sup>356</sup>→Trp, Ile<sup>172</sup>→ Asn, and Val<sup>281</sup> → Leu. Ten patients were compound heterozygotes.</p><p><em>Conclusions:</em> In general, the magnitude of enzyme activity correlates with the phenotypic findings. For example, mutations that completely impair enzyme activity, such as homozygous deletions of the promoter region, are associated with salt-losing congenital adrenal hyperplasia. However, the splicing mutation at nucleotide 655 in the second intron is characterized by greater phenotypic heterogeneity than the other mutations in this series.</p></div>","PeriodicalId":80358,"journal":{"name":"Adolescent and pediatric gynecology","volume":"8 1","pages":"Pages 9-16"},"PeriodicalIF":0.0000,"publicationDate":"1995-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0932-8610(12)80154-X","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Adolescent and pediatric gynecology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093286101280154X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19
Abstract
Study Objective: To correlate phenotype with genotype based on molecular diagnosis in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Design: Polymerase chain reaction amplification, restriction fragment length polymorphism, and allele specific oligonucleotide hybridization were utilized to ascertain eight previously recognized deleterious mutations in affected individuals and their family members.
Participants/Setting: DNA samples were obtained from 20 individuals with 21-hydroxylase deficiency followed through the Endocrine Clinic of the Children's Hospital of Pittsburgh. Fifteen individuals had salt-losing 21-hydroxylase deficiency and two families had two affected individuals. Four individuals presented prior to 5 years of age without salt loss. One individual presented in adolescence with hirsutism and oligomenorrhea.
Main Outcome Measure: Molecular diagnosis of 21-hydroxylase deficiency.
Results: Five patients have homozygous deletions of the promoter region. Two patients are homozygous for the splicing mutation in the second intron. Individual patients were homozygous for the following three mutations: Arg356→Trp, Ile172→ Asn, and Val281 → Leu. Ten patients were compound heterozygotes.
Conclusions: In general, the magnitude of enzyme activity correlates with the phenotypic findings. For example, mutations that completely impair enzyme activity, such as homozygous deletions of the promoter region, are associated with salt-losing congenital adrenal hyperplasia. However, the splicing mutation at nucleotide 655 in the second intron is characterized by greater phenotypic heterogeneity than the other mutations in this series.